{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T22:12:51Z","timestamp":1773094371049,"version":"3.50.1"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2012,2,4]],"date-time":"2012-02-04T00:00:00Z","timestamp":1328313600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Treat Options Neurol"],"published-print":{"date-parts":[[2012,4]]},"DOI":"10.1007\/s11940-012-0168-7","type":"journal-article","created":{"date-parts":[[2012,2,3]],"date-time":"2012-02-03T02:55:47Z","timestamp":1328237747000},"page":"126-136","source":"Crossref","is-referenced-by-count":31,"title":["Treatment Options for Tauopathies"],"prefix":"10.1007","volume":"14","author":[{"given":"Tarik","family":"Karakaya","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabian","family":"Fu\u00dfer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Prvulovic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harald","family":"Hampel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2012,2,4]]},"reference":[{"key":"168_CR1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00401-010-0706-x","volume":"120","author":"K Wakabayashi","year":"2010","unstructured":"Wakabayashi K, Mori F, Tanji K, et al. Involvement of the peripheral nervous system in synucleinopathies, tauopathies and other neurodegenerative proteinopathies of the brain. Acta Neuropathol. 2010;120:1\u201312.","journal-title":"Acta Neuropathol"},{"key":"168_CR2","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1038\/ncpneuro0357","volume":"2","author":"S Sha","year":"2006","unstructured":"Sha S, Hou C, Viskontas IV, Miller BL. Are frontotemporal lobar degeneration, progressive supranuclear palsy and corticobasal degeneration distinct diseases? Nat Clin Pract Neurol. 2006;2:658\u201365.","journal-title":"Nat Clin Pract Neurol"},{"issue":"3","key":"168_CR3","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1007\/s12031-011-9632-1","volume":"45","author":"AJ Espay","year":"2011","unstructured":"Espay AJ, Litvan I. Parkinsonism and frontotemporal dementia: the clinical overlap. J Mol Neurosci. 2011;45(3):343\u20139.","journal-title":"J Mol Neurosci"},{"key":"168_CR4","doi-asserted-by":"crossref","first-page":"375","DOI":"10.2165\/11533100-000000000-00000","volume":"24","author":"GD Rabinovici","year":"2010","unstructured":"Rabinovici GD, Miller BL. Frontotemporal lobar degeneration: epidemiology, pathophysiology, diagnosis and management. CNS Drugs. 2010;24:375\u201398.","journal-title":"CNS Drugs"},{"key":"168_CR5","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.nurt.2008.05.006","volume":"3","author":"A Schneider","year":"2008","unstructured":"Schneider A, Mandelkow E. Tau-based treatment strategies in neurodegenerative diseases. Neurotherapeutics. 2008;3:443\u201357.","journal-title":"Neurotherapeutics"},{"issue":"3","key":"168_CR6","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1007\/s12031-011-9615-2","volume":"45","author":"KP Rankin","year":"2011","unstructured":"Rankin KP, Mayo MC, Seeley WW, et al. Behavioral variant frontotemporal dementia with corticobasal degeneration pathology: phenotypic comparison to bvFTD with Pick\u2019s disease. J Mol Neurosci. 2011;45(3):594\u2013608.","journal-title":"J Mol Neurosci."},{"issue":"4","key":"168_CR7","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/j.pneurobio.2011.04.012","volume":"95","author":"WT Hu","year":"2011","unstructured":"Hu WT, Trojanowski JQ, Shaw LM. Biomarkers in frontotemporal lobar degenerations\u2013progress and challenges. Prog Neurobiol. 2011;95(4):636\u201348.","journal-title":"Prog Neurobiol."},{"key":"168_CR8","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1212\/01.wnl.0000191304.55196.4d","volume":"66","author":"ED Huey","year":"2006","unstructured":"Huey ED, Putnam KT, Grafman J. A systematic review of neurotransmitter deficits and treatments in frontotemporal dementia. Neurology. 2006;66:17\u201322.","journal-title":"Neurology"},{"key":"168_CR9","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S1474-4422(10)70299-4","volume":"10","author":"O Piguet","year":"2011","unstructured":"Piguet O, Hornberger M, Mioshi E, Hodges JR. Behavioural-variant frontotemporal dementia: diagnosis, clinical staging, and management. Lancet Neurol. 2011;10:162\u201372.","journal-title":"Lancet Neurol"},{"key":"168_CR10","unstructured":"Herrmann N, Black SE, Chow T, et al. Serotonergic function and treatment of behavioral and psychological symptoms of frontotemporal dementia. Am J Geriatr Psychiatry. 2011 Nov 4 (Epub ahead of print)."},{"key":"168_CR11","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1159\/000197896","volume":"24","author":"MF Mendez","year":"2009","unstructured":"Mendez MF. Frontotemporal dementia: therapeutic interventions. Front Neurol Neurosci. 2009;24:168\u201378.","journal-title":"Front Neurol Neurosci"},{"key":"168_CR12","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1016\/S1734-1140(10)70366-2","volume":"62","author":"M Kuszczyk","year":"2010","unstructured":"Kuszczyk M, S\u0142omka M, Antkiewicz-Michaluk L, et al. 1-Methyl-1,2,3,4-tetrahydroisoquinoline and established uncompetitive NMDA receptor antagonists induce tolerance to excitotoxicity. Pharmacol Rep. 2010;62:1041\u201350.","journal-title":"Pharmacol Rep"},{"key":"168_CR13","doi-asserted-by":"crossref","first-page":"415","DOI":"10.2147\/NDT.S22635","volume":"7","author":"TW Chow","year":"2011","unstructured":"Chow TW, Graff-Guerrero A, Verhoeff NP, et al. Open-label study of the short-term effects of memantine on FDG-PET in frontotemporal dementia. Neuropsychiatr Dis Treat. 2011;7:415\u201324.","journal-title":"Neuropsychiatr Dis Treat"},{"key":"168_CR14","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1080\/15622970601016538","volume":"8","author":"A Fellgiebel","year":"2007","unstructured":"Fellgiebel A, M\u00fcller MJ, Hiemke C, et al. Clinical improvement in a case of frontotemporal dementia under aripiprazole treatment corresponds to partial recovery of disturbed frontal glucose metabolism. World J Biol Psychiatry. 2007;8:123\u20136.","journal-title":"World J Biol Psychiatry"},{"key":"168_CR15","doi-asserted-by":"crossref","first-page":"52","DOI":"10.2174\/156720508783884657","volume":"5","author":"C Hickey","year":"2008","unstructured":"Hickey C, Chisholm T, Passmore MJ, et al. Differentiating the dementias. revisiting synucleinopathies and tauopathies. Curr Alzheimer Res. 2008;5:52\u201360.","journal-title":"Curr Alzheimer Res"},{"key":"168_CR16","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1097\/WCO.0b013e3283480569","volume":"24","author":"GK Wenning","year":"2011","unstructured":"Wenning GK, Krismer F, Poewe W. New insights into atypical parkinsonism. Curr Opin Neurol. 2011;24:331\u20138.","journal-title":"Curr Opin Neurol"},{"key":"168_CR17","first-page":"40","volume":"12","author":"F Geser","year":"2005","unstructured":"Geser F, Wenning GK. Klinik und Therapie der Multisystematrophie und progressiven supranukle\u00e4ren Paralyse. Psychopharmakotherapie. 2005;12:40\u201350. German","journal-title":"Psychopharmakotherapie"},{"key":"168_CR18","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1590\/S0004-282X2010000600020","volume":"68","author":"OG Barsottini","year":"2010","unstructured":"Barsottini OG, Fel\u00edcio AC, Aquino CC, Pedroso JL. Progressive supranuclear palsy: new concepts. Arq Neuropsiquiatr. 2010;68:938\u201346.","journal-title":"Arq Neuropsiquiatr"},{"key":"168_CR19","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.jalz.2009.04.1231","volume":"6","author":"I Liepelt","year":"2010","unstructured":"Liepelt I, Gaenslen A, Godau J, et al. Rivastigmine for the treatment of dementia in patients with progressive supranuclear palsy: clinical observations as a basis for power calculations and safety analysis. Alzheimers Dement. 2010;6:70\u20134.","journal-title":"Alzheimers Dement"},{"key":"168_CR20","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1111\/j.1468-1331.2008.02513.x","volume":"16","author":"AC Ludolph","year":"2009","unstructured":"Ludolph AC, Kassubek J, Landwehrmeyer BG, et al. Tauopathies with parkinsonism: clinical spectrum, neuropathologic basis, biological markers, and treatment options. Eur J Neurol. 2009;16:297\u2013309.","journal-title":"Eur J Neurol"},{"key":"168_CR21","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1002\/mds.23713","volume":"26","author":"GK Wenning","year":"2011","unstructured":"Wenning GK, Litvan I, Tolosa E. Milestones in atypical and secondary Parkinsonisms. Mov Disord. 2011;26:1083\u201395.","journal-title":"Mov Disord"},{"key":"168_CR22","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1159\/000101337","volume":"23","author":"I Liepelt","year":"2007","unstructured":"Liepelt I, Maetzler W, Blaicher HP, et al. Treatment of dementia in parkinsonian syndromes with cholinesterase inhibitors. Dement Geriatr Cogn Disord. 2007;23:351\u201367.","journal-title":"Dement Geriatr Cogn Disord"},{"key":"168_CR23","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1196\/annals.1427.027","volume":"1147","author":"RK Chaturvedi","year":"2008","unstructured":"Chaturvedi RK, Beal MF. Mitochondrial approaches for neuroprotection. Ann N Y Acad Sci. 2008;1147:395\u2013412.","journal-title":"Ann N Y Acad Sci"},{"key":"168_CR24","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1002\/mds.20465","volume":"20","author":"MF Mendez","year":"2005","unstructured":"Mendez MF, Shapira JS, Miller BL. Stereotypical movements and frontotemporal dementia. Mov Disord. 2005;20:742\u20135.","journal-title":"Mov Disord"},{"key":"168_CR25","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/S0033-3182(98)71313-1","volume":"39","author":"R Hargrave","year":"1998","unstructured":"Hargrave R, Rafal R. Depression in corticobasal degeneration. Psychosomatics. 1998;39:481\u20132.","journal-title":"Psychosomatics"},{"key":"168_CR26","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1159\/000067021","volume":"49","author":"R Moretti","year":"2003","unstructured":"Moretti R, Torre P, Antonello RM, et al. Frontotemporal dementia: paroxetine as a possible treatment of behavior symptoms. A randomized, controlled, open 14-month study. Eur Neurol. 2003;49:13\u20139.","journal-title":"Eur Neurol"},{"key":"168_CR27","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1007\/s00213-003-1686-5","volume":"172","author":"JB Deakin","year":"2004","unstructured":"Deakin JB, Rahman S, Nestor PJ, et al. Paroxetine does not improve symptoms and impairs cognition in frontotemporal dementia: a double-blind randomized controlled trial. Psychopharmacology. 2004;172:400\u20138.","journal-title":"Psychopharmacology"},{"key":"168_CR28","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.parkreldis.2006.04.002","volume":"12","author":"E Friess","year":"2006","unstructured":"Friess E, Kuempfel T, Modell S, et al. Paroxetine treatment improves motor symptoms in patients with multiple system atrophy. Parkinsonism Relat Disord. 2006;12:432\u20137.","journal-title":"Parkinsonism Relat Disord"},{"key":"168_CR29","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1212\/WNL.55.8.1216","volume":"55","author":"R Ceravolo","year":"2000","unstructured":"Ceravolo R, Nuti A, Piccinni A, et al. Paroxetine in Parkinson\u2019s disease: effects on motor and depressive symptoms. Neurology. 2000;55:1216\u20138.","journal-title":"Neurology"},{"key":"168_CR30","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1159\/000076343","volume":"17","author":"M Ikeda","year":"2004","unstructured":"Ikeda M, Shigenobu K, Fukuhara R, et al. Efficacy of fluvoxamine as a treatment for behavioral symptoms in frontotemporal lobar degeneration patients. Dement Geriatr Cogn Disord. 2004;17:117\u201321.","journal-title":"Dement Geriatr Cogn Disord"},{"key":"168_CR31","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1159\/000077171","volume":"17","author":"F Lebert","year":"2004","unstructured":"Lebert F, Stekke W, Hasenbroekx C, Pasquier F. Frontotemporal dementia: a randomised, controlled trial with trazodone. Dement Geriatr Cogn Disord. 2004;17:355\u20139.","journal-title":"Dement Geriatr Cogn Disord"},{"key":"168_CR32","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1097\/01.JGP.0000231744.69631.33","volume":"15","author":"MF Mendez","year":"2007","unstructured":"Mendez MF, Shapira JS, McMurtray A, et al. Preliminary findings: behavioral worsening on donepezil in patients with frontotemporal dementia. Am J Geriatr Psychiatry. 2007;15:84\u20137.","journal-title":"Am J Geriatr Psychiatry"},{"key":"168_CR33","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1212\/01.wnl.0000214662.19840.ea","volume":"66","author":"JM Miyasaki","year":"2006","unstructured":"Miyasaki JM, Shannon K, Voon V, et al. Practice parameter: evaluation and treatment of depression, psychosis, and dementia in Parkinson disease (an evidence-based review) \u2013 Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2006;66:966\u20131002.","journal-title":"Neurology"},{"key":"168_CR34","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1212\/WNL.57.3.467","volume":"57","author":"I Litvan","year":"2001","unstructured":"Litvan I, Phipps M, Pharr VL, et al. Randomized placebo-controlled trial of donepezil in patients with progressive supranuclear palsy. Neurology. 2001;57:467\u201373.","journal-title":"Neurology"},{"key":"168_CR35","doi-asserted-by":"crossref","first-page":"931","DOI":"10.2165\/00002512-200421140-00003","volume":"21","author":"R Moretti","year":"2004","unstructured":"Moretti R, Torre P, Antonello RM, et al. Rivastigmine in frontotemporal dementia: an open-label study. Drugs Aging. 2004;21:931\u20137.","journal-title":"Drugs Aging"},{"key":"168_CR36","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1056\/NEJMoa041470","volume":"351","author":"M Emre","year":"2004","unstructured":"Emre M, Aarsland D, Albanese A, et al. Rivastigmine for dementia associated with Parkinson\u2019s disease. N Engl J Med. 2004;351:2509\u201318.","journal-title":"N Engl J Med"},{"key":"168_CR37","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1016\/S0140-6736(00)03399-7","volume":"356","author":"I McKeith","year":"2000","unstructured":"McKeith I, Del Ser T, Spano P, et al. Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study. Lancet. 2000;356:2031\u20136.","journal-title":"Lancet"},{"key":"168_CR38","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1159\/000113034","volume":"25","author":"A Kertesz","year":"2008","unstructured":"Kertesz A, Morlog D, Light M, et al. Galantamine in frontotemporal dementia and primary progressive aphasia. Dement Geriatr Cogn Disord. 2008;25:178\u201385.","journal-title":"Dement Geriatr Cogn Disord"},{"key":"168_CR39","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1002\/gps.1973","volume":"23","author":"J Diehl-Schmid","year":"2008","unstructured":"Diehl-Schmid J, F\u00f6rstl H, Perneczky R, et al. A 6-month, open-label study of memantine in patients with frontotemporal dementia. Int J Geriatr Psychiatry. 2008;23:754\u20139.","journal-title":"Int J Geriatr Psychiatry"},{"key":"168_CR40","doi-asserted-by":"crossref","first-page":"749","DOI":"10.3233\/JAD-2010-101632","volume":"23","author":"M Vercelletto","year":"2011","unstructured":"Vercelletto M, Boutoleau-Bretonni\u00e8re C, Volteau C, et al. Memantine in behavioral variant frontotemporal dementia: negative results. J Alzheimers Dis. 2011;23:749\u201359.","journal-title":"J Alzheimers Dis"},{"key":"168_CR41","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/S1474-4422(09)70146-2","volume":"8","author":"D Aarsland","year":"2009","unstructured":"Aarsland D, Ballard C, Walker Z, et al. Memantine in patients with Parkinson\u2019s disease dementia or dementia with Lewy bodies: a double-blind, placebo-controlled, multicentre trial. Lancet Neurol. 2009;8:613\u20138.","journal-title":"Lancet Neurol"},{"key":"168_CR42","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1097\/WAD.0b013e318197852f","volume":"23","author":"AL Boxer","year":"2009","unstructured":"Boxer AL, Lipton AM, Womack K, et al. An open-label study of memantine treatment in 3 subtypes of frontotemporal lobar degeneration. Alzheimer Dis Assoc Disord. 2009;23:211\u20137.","journal-title":"Alzheimer Dis Assoc Disord"},{"key":"168_CR43","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1001\/archneurol.2011.139","volume":"68","author":"D Weintraub","year":"2011","unstructured":"Weintraub D, Chen P, Ignacio RV, et al. Patterns and trends in antipsychotic prescribing for Parkinson disease psychosis. Arch Neurol. 2011;68:899\u2013904.","journal-title":"Arch Neurol"},{"key":"168_CR44","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.jalz.2007.06.001","volume":"4","author":"JQ Trojanowski","year":"2008","unstructured":"Trojanowski JQ, Duff K, Fillit H, et al. New directions for frontotemporal dementia drug discovery. Alzheimers Dement. 2008;4:89\u201393.","journal-title":"Alzheimers Dement"}],"container-title":["Current Treatment Options in Neurology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11940-012-0168-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11940-012-0168-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11940-012-0168-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,23]],"date-time":"2019-06-23T01:35:26Z","timestamp":1561253726000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11940-012-0168-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,2,4]]},"references-count":44,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2012,4]]}},"alternative-id":["168"],"URL":"https:\/\/doi.org\/10.1007\/s11940-012-0168-7","relation":{},"ISSN":["1092-8480","1534-3138"],"issn-type":[{"value":"1092-8480","type":"print"},{"value":"1534-3138","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,2,4]]}}}